Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In the univariate COX analysis in the group with a NT-proBNP ≤ 125 pg/mL, the variables that were predictors with a p < 0.2 of the development of the primary objective were Caucasian, age, high blood pressure, treatment with statins, ezetimibe, betablockers, mineralocorticoid receptor antagonists, nitrates, calcium antagonists, and analytical parameters such as glucose, total cholesterol, LDL, non-HDL, calcidiol and PTH (Table 2A).

Source: 3.3. Prognostic Value of the Components of Mineral Metabolism According to NT-proBNP. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

These patients were part of the BACS & BAMI (Biomarkers in Acute Coronary Syndrome & Biomarkers in Acute Myocardial Infarction) studies, carried out in five hospitals in the Community of Madrid.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease

Study design awaiting verification · Journal of Clinical Medicine · 2022

Original publication title

NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease

Juan Martínez-Milla; Álvaro Aceña; Ana Pello; Marta López-Castillo; Hans Paul Gaebelt; Óscar González-Lorenzo; Nieves Tarín; Carmen Cristóbal; Luis M. Blanco-Colio; José Luis Martín-Ventura; Ana Huelmos; Andrea Kallmeyer; Joaquín Alonso; Carlos Gutiérrez-Landaluce; Lorenzo López Bescós; Jesús Egido; Ignacio Mahíllo-Fernández; Óscar Lorenzo; María Luisa González-Casaus; José Tuñón

© 2022 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background. Mineral metabolism (MM) system and N-terminal pro-brain natriuretic peptide (NT-ProBNP) have been shown to add prognostic value in patients with stable coronary artery disease (SCAD). However, the influence of NT-ProBNP on the prognostic role of MM in patients with SCAD has not been shown yet. The objective of this study is to assess the influence of NT-ProBNP on the prognostic role of MM markers in patients with SCAD. Methods: We analyzed the prognostic value of MM markers (parathormone (PTH), klotho, phosphate, calcidiol (25-hydroxyvitamin D3), and fibroblast growth factor-23) in 964 patients with SCAD and NT-ProBNP > 125 pg/mL vs. patient with NT-ProBNP ≤ 125 pg/mL included in five hospitals in Spain.

The main outcome was the combination of death, heart failure, and ischemic events (any acute coronary syndrome, ischemic stroke, or transient ischemic attack). Results: A total of 622 patients had NT-proBNP > 125 pg/mL and 342 patients had NT-ProBNP ≤ 125 pg/mL. The median follow-up was 5.1 years. In the group of NT-proBNP > 125 pg/mL, the patients were older, and there were more females and smokers than in the group of patients with normal NT-proBNP. Additionally, the proportion of patients with hypertension, atrial fibrillation, ejection fraction < 40%, cerebrovascular attack, or prior coronary artery bypass graft was higher in the high NT-proBNP group.

In the high NT-proBNP patients, the predictors of poor prognosis were PTH (HR = 1.06 (1.01 to 1.10), p < 0.001) and NT-proBNP (HR = 1.02 (1.01 to 1.03), p = 0.011), along with age (HR = 1.039 (1.02 to 1.06), p < 0.001), prior coronary artery bypass graft (HR = 1.624 (1.02 to 2.59), p = 0.041), treatment with statins (HR = 0.32 (0.19 to 0.53), p < 0.001), insulin (HR = 2.49 (1.59 to 4.09), p < 0.001), angiotensin receptor blockers (HR = 1.73 (1.16 to 2.56), p = 0.007), nitrates (HR = 1.65 (1.10 to 2.45), p = 0.014), and proton pump inhibitors (HR = 2.75 (1.74 to 4.36), p < 0.001).

In the NT-proBNP ≤ 125 pg/mL subgroup, poor prognosis predictors were plasma levels of non-high-density lipoprotein (non-HDL) cholesterol (HR = 1.01 (1.00 to 1.02), p = 0.014) and calcidiol (HR = 0.96 (0.92 to 0.99), p = 0.045), as well as treatment with verapamil (HR = 11.28 (2.54 to 50.00), p = 0.001), and dihydropyridines (HR = 3.16 (1.63 to 6.13), p = 0.001). Conclusion: In patients with SCAD and NT-ProBNP > 125 pg/mL, PTH and NT-ProBNP, which are markers related to ventricular damage, are predictors of poor outcome.

In the subgroup of patients with NT-ProBNP ≤ 125 pgm/L, calcidiol and non-HDL cholesterol, which are more related to vascular damage, are the independent predictors of poor outcome. Then, in patients with SCAD, baseline NT-ProBNP may influence the type of biomarker that is effective in risk prediction.

Authors’ abstract

Background. Mineral metabolism (MM) system and N-terminal pro-brain natriuretic peptide (NT-ProBNP) have been shown to add prognostic value in patients with stable coronary artery disease (SCAD). However, the influence of NT-ProBNP on the prognostic role of MM in patients with SCAD has not been shown yet. The objective of this study is to assess the influence of NT-ProBNP on the prognostic role of MM markers in patients with SCAD. Methods: We analyzed the prognostic value of MM markers (parathormone (PTH), klotho, phosphate, calcidiol (25-hydroxyvitamin D3), and fibroblast growth factor-23) in 964 patients with SCAD and NT-ProBNP > 125 pg/mL vs. patient with NT-ProBNP ≤ 125 pg/mL included in five hospitals in Spain.

The main outcome was the combination of death, heart failure, and ischemic events (any acute coronary syndrome, ischemic stroke, or transient ischemic attack). Results: A total of 622 patients had NT-proBNP > 125 pg/mL and 342 patients had NT-ProBNP ≤ 125 pg/mL. The median follow-up was 5.1 years. In the group of NT-proBNP > 125 pg/mL, the patients were older, and there were more females and smokers than in the group of patients with normal NT-proBNP. Additionally, the proportion of patients with hypertension, atrial fibrillation, ejection fraction < 40%, cerebrovascular attack, or prior coronary artery bypass graft was higher in the high NT-proBNP group.

In the high NT-proBNP patients, the predictors of poor prognosis were PTH (HR = 1.06 (1.01 to 1.10), p < 0.001) and NT-proBNP (HR = 1.02 (1.01 to 1.03), p = 0.011), along with age (HR = 1.039 (1.02 to 1.06), p < 0.001), prior coronary artery bypass graft (HR = 1.624 (1.02 to 2.59), p = 0.041), treatment with statins (HR = 0.32 (0.19 to 0.53), p < 0.001), insulin (HR = 2.49 (1.59 to 4.09), p < 0.001), angiotensin receptor blockers (HR = 1.73 (1.16 to 2.56), p = 0.007), nitrates (HR = 1.65 (1.10 to 2.45), p = 0.014), and proton pump inhibitors (HR = 2.75 (1.74 to 4.36), p < 0.001).

In the NT-proBNP ≤ 125 pg/mL subgroup, poor prognosis predictors were plasma levels of non-high-density lipoprotein (non-HDL) cholesterol (HR = 1.01 (1.00 to 1.02), p = 0.014) and calcidiol (HR = 0.96 (0.92 to 0.99), p = 0.045), as well as treatment with verapamil (HR = 11.28 (2.54 to 50.00), p = 0.001), and dihydropyridines (HR = 3.16 (1.63 to 6.13), p = 0.001). Conclusion: In patients with SCAD and NT-ProBNP > 125 pg/mL, PTH and NT-ProBNP, which are markers related to ventricular damage, are predictors of poor outcome.

In the subgroup of patients with NT-ProBNP ≤ 125 pgm/L, calcidiol and non-HDL cholesterol, which are more related to vascular damage, are the independent predictors of poor outcome. Then, in patients with SCAD, baseline NT-ProBNP may influence the type of biomarker that is effective in risk prediction.

Publication and source details

Original title: NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease

Juan Martínez-Milla; Álvaro Aceña; Ana Pello; Marta López-Castillo; Hans Paul Gaebelt; Óscar González-Lorenzo; Nieves Tarín; Carmen Cristóbal; Luis M. Blanco-Colio; José Luis Martín-Ventura; Ana Huelmos; Andrea Kallmeyer; Joaquín Alonso; Carlos Gutiérrez-Landaluce; Lorenzo López Bescós; Jesús Egido; Ignacio Mahíllo-Fernández; Óscar Lorenzo; María Luisa González-Casaus; José Tuñón

Journal of Clinical Medicine · 2022

* Correspondence: jtunon@fjd.es© 2022 by the authors.2022https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Instituto de Salud Carlos IIIFondos FEDER (Fondo Europeo de Desarrollo Regional) European UnionPI05/0451PI14/1567PI17/01615PI17/01495PI19/00128PI20/487PI20/923Ministry of Science and InnovationRTC2019-006826-1DTS 19/00093RECAVA (Red Temática de Investigación CooperativaenEnfermedadesCardiovasculares)RD06/0014/0035Instituto de Salud Carlos III FEDERRD09/0076/00101This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER (Fondo Europeo de Desarrollo Regional) European Union (PI05/0451, PI14/1567, PI17/01615, PI17/01495, PI19/00128, PI20/487, and PI20/923); RETOS-Colaboración, Ministry of Science and Innovation (RTC2019-006826-1, DTS 19/00093) Spanish Society of Arteriosclerosis; RECAVA (Red Temática de Investigación CooperativaenEnfermedadesCardiovasculares) (RD06/0014/0035); and Instituto de Salud Carlos III FEDER (FJD biobank: RD09/0076/00101). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T09:41:46.555600+00:00

DOI: 10.3390/jcm11144153 · PMC9319637